A prospective, multi-Institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 11, 2013, Pages 1545-1549

  Viray Dr , Hollis ^a   Li, Kevin ^a   Long, Thomas A ^b   Vasalos, Patricia ^b   Bridge Dr , Julia A ^c   Jennings Dr , Lawrence J ^d   Halling, Kevin C ^e   Hameed Dr , Meera ^f   Rimm Dr , David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Molecular Pathology Division   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e MAYO CLINIC   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADENOCARCINOMA; ARTICLE; CELL COUNT; CLINICAL TRIAL; COLON TUMOR; GENETICS; HUMAN; INFORMATION PROCESSING; LABORATORY; MEDICAL SOCIETY; MULTICENTER STUDY; MUTATION; NEOPLASM; OBSERVER VARIATION; ONCOGENE RAS; PATHOLOGY; PROSPECTIVE STUDY; UNITED STATES;

ADENOCARCINOMA; CELL COUNT; COLONIC NEOPLASMS; DATA COLLECTION; GENES, RAS; HUMANS; LABORATORIES; MUTATION; NEOPLASMS; OBSERVER VARIATION; PATHOLOGY, CLINICAL; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84887830506     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0561-CP     Document Type: Article

References (18)

1. Warth A, Penzel R, Brandt R, et al. Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. Virchows Arch. 2012;460(4):407-414
2. Bellon E, Ligtenberg MJ, Tejpar S, et al. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist. 2011;16(4):467-478
3. Lamy A, Blanchard F, Le Pessot F, et al. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Mod Pathol. 2011;24(8):1090-1100
4. Pont-Kingdon G, Gedge F, Wooderchak-Donahue W, et al. Design and analytical validation of clinical DNA sequencing assays. Arch Pathol Lab Med. 2011;136(1):41-46
5. Anderson S, Bloom KJ, Vallera DU, et al. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med. 2012;136(11):1385-1391
6. Angulo B, García-García E, Martínez R, et al. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn. 2010;12(3): 292-299
7. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091-2096
8. Weichert W, Schewe C, Lehmann A, et al. KRAS genotyping of paraffinembedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn. 2010;12(1):35-42
9. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414-4422
10. Peintinger F, Anderson K, Mazouni C, et al. Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer. Clin Cancer Res. 2007;13(14):4078-4082
11. Nahleh Z, Sivasubramaniam D, Dhaliwal S, Sundarajan V, Komrokji R. Residual cancer burden in locally advanced breast cancer: a superior tool. Curr Oncol. 2008;15(6):17-24
12. Peintinger F, Buzdar AU, Kuerer HM, et al. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol. 2008;19(12):2020-2025
13. Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev. 2011;32(4):177-195
14. Natrajan R, Reis-Filho JS. Next-generation sequencing applied to molecular diagnostics. Expert Rev Mol Diagn. 2011;11(4):425-444
15. Talkowski ME, Ernst C, Heilbut A, et al. Next-generation sequencing strategies enable routine detection of balanced chromosome rearrangements for clinical diagnostics and genetic research. Am J Hum Genet. 2011;88(4):469-481
16. Smeets SJ, Harjes U, Van Wieringen WN, et al. To DNA or not to DNA? That is the question, when it comes to molecular subtyping for the clinic! Clin Cancer Res. 2011;17(15):4959-4964
17. Dequeker E, Ligtenberg M, Vander Borght S, Van Krieken J. Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme. Virchows Arch. 2011;459(2):155-160
18. Thunnissen E, Bovée JVMG, Bruinsma H, et al. EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy. J Clin Pathol. 2011;64(10):884-892